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A B S T R A C T
Biological monitoring and physiologically-based pharmacokinetic (PBPK) modelling are useful complementary
tools in quantifying human exposure to elements in the environment. In this work, we used PBPK models to
determine the optimal time for collecting biological samples in a longitudinal study to determine if participants
who consumed allotment produce had been exposed to arsenic, cadmium, chromium, nickel or lead. There are a
number of PBPK models for these elements published in the literature, which vary in size, complexity and
application, given the diﬀerences in physiochemical properties of the elements, organs involved in metabolism
and exposure pathways aﬀected. We selected PBPK models from the literature to simulate the oral ingestion
pathway from consumption of allotment produce. Some models required modiﬁcation by reducing or removing
selected compartments whilst still maintaining their original predictability. The performance of the modiﬁed
models was evaluated by comparing the predicted urinary and blood elemental levels with experimental data
and other model simulations published in the literature. Overall, the model predictions were consistent with
literature data (r > 0.7, p < 0.05), and were inﬂuential in predicting when samples should be collected. Our
results demonstrate the use of mathematical modelling in informing and optimising the design of longitudinal
studies.
1. Introduction
Arsenic (As), cadmium (Cd), chromium (Cr), nickel (Ni) and lead
(Pb) are known to occur in urban horticultural sites (allotments) and
gardens, as a result of pollution from traﬃc, general urban activities,
industrial emissions and the actions of allotment tenants (Bechet et al.,
2016; Kelly et al., 1996; Alloway, 2004). Fruits and vegetables grown in
contaminated soil may lead to humans ingesting these elements
through the consumption of home grown produce. According to the
Environment Agency (2009), the consumption rates for allotment pro-
duce by adults in the United Kingdom (UK) range from 0.22 to 2.97
(g−1 fresh weight (fw) kg−1 body weight (bw) day−1), depending on
the produce categories used in the Contaminated Land Exposure As-
sessment (CLEA) model. The CLEA model, a tool used in the UK to
assess human exposure to soil contaminants, groups allotment produce
into six categories (green, root, tuber, herbaceous, shrub and tree)
(Environment Agency, 2009). The toxicological eﬀects of these ele-
ments are well documented and As, Cd, Cr and Ni are Group 1 inorganic
human carcinogens (IARC, 2012). Oral exposure to Pb can cause toxic
eﬀects on various body organs and tissues including kidney dysfunc-
tion, cardiovascular eﬀects (e.g., increase in blood pressure), gastro-
intestinal eﬀects (e.g., colic), haematological eﬀects (e.g., anaemia),
and brain damage (ATSDR, 2007).
Biological monitoring (biomonitoring) and physiologically-based
pharmacokinetic (PBPK) modelling are useful tools in quantifying
human exposure to elements in the environment; they are com-
plementary in exposure studies (Clewell et al., 2008; Lyons et al.,
2008). Human biomonitoring is the assessment of an individual’s ex-
posure to an element or compound through the measurement of a
biomarker (e.g., blood, urine) which results from exposure to that
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element (Coelho et al., 2014). Meanwhile, physiologically-based phar-
macokinetic (PBPK) modelling involves predicting the fate of elements
in the body (Schmitt and Willmann, 2005), using physiological and
biochemical information to describe and quantify the pharmacokinetic
processes aﬀecting the absorption, distribution, methylation (bio-
transformation) and excretion of an element (Wen et al., 1999). PBPK
models are based on compartments (e.g., body organs, tissues) and the
interconnections among them. The level of model detail relates to the
compartments and elements (including associated chemical forms such
as metabolites) that are tracked within the model (Krishnan et al.,
2010). PBPK models provide a scientiﬁc basis for quantitatively esti-
mating risk to human health (Yu, 1999).
In this paper, our aim is to use PBPK models to determine the op-
timal time for collecting biological samples to determine if participants
who consumed allotment produce during a longitudinal biomonitoring
study had been exposed to As, Cd, Cr, Ni or Pb. To do this, we sought to
obtain applicable published PBPK and physiologically-based tox-
icokinetic (PBTK) models for these elements from the literature. Some
of these models are quite complex in terms of their structure and for-
mulation because of the diﬀerences in physiochemical properties of the
elements, organs involved in metabolism and exposure pathways si-
mulated by the authors. For example, PBPK models for As published by
the El-Masri and Kenyon (2008), Liao et al. (2008), Yu (1999) and
Mann et al. (1996) indicate that As undergoes biotransformation into
diﬀerent species within the body, with kidney and liver being the key
organs for As methylation. The Cr models published by Finley et al.
(1997), O’Flaherty et al. (2001) and Kirman et al. (2013) indicate that
Cr species undergo oxidation and reduction in the body. No biological
transformations are shown to occur in the models for Cd (Kjellstrom
and Nordberg, 1978), Ni (Sunderman et al., 1989) and Pb (Fleming
et al., 1999; White et al., 1998; O’Flaherty, 1993). Due to the structural
complexity of some of the models, to construct models suitable for our
purpose, some of the published models required modiﬁcation by re-
ducing or removing some compartments whilst maintaining their pre-
dictive ability.
The objectives of this part of our research were: (i) to review pub-
lished PBPK and PBTK models for these elements and select models for
use in our study; (ii) to make the necessary modiﬁcations to the models
to ﬁt our purpose (i.e., to use the models to determine the optimal time
for collecting biological samples); (iii) to evaluate their predictive
performance by comparing the reduced model predictions with data
published in the literature; and (iv) to use the modiﬁed models to
predict optimal times (following oral exposure to the elements) for
collecting biological samples during our biomonitoring study, in order
to maximise the detection of the elements in urine and blood samples.
Based on the consumption of allotment produce, we set out to in-
vestigate human exposure to As, Cd, Cr, Ni and Pb from soil with low
levels of these elements. We identiﬁed 30 allotment sites across central
Scotland, UK with varying levels of toxic element contamination.
Allotment users (36 adults) were recruited to participate in the study.
Informed consent was obtained from each participant and ethical ap-
proval was granted by the University of Reading Research Ethics
Committee (UREC), approval reference UREC 15/21.
2. Methods
2.1. Model selection
We reviewed previously published PBPK/PBTK models for As, Cd,
Cr, Ni and Pb in humans, and selected suitable ones based on whether
the model was reproducible, relevant to adult humans, included a de-
scription of the oral ingestion pathway, and the most recent/most used
model. The mathematical equations for each modiﬁed model are given
in the Supplementary material along with the schematic details of the
original models obtained from the literature (Figs. S1–S5). The
physiological and chemical-speciﬁc parameters were obtained from the
literature and are detailed in Tables S1 to S5 of the Supplementary
material. In the following sections, we detail the models selected for
each toxic element and the modiﬁcations made to the original pub-
lished models.
2.2. Arsenic
We identiﬁed a number of human PBPK models for inorganic As
published in the literature (Mann et al., 1996; El-Masri and Kenyon,
2008; Liao et al., 2008; Yu, 1999). These models are largely similar in
structure, and they account for oxidation of trivalent inorganic As (As
(III)) to its pentavalent form (As(V)), reduction of As(V) to As(III), and
methylation of As(III) to monomethylarsenic acid (MMA) and di-
methylarsinic acid (DMA) in the body. The model by Mann et al. (1996)
included both oral and inhalation exposure pathways, whereas other
models only included the ingestion pathway. Ingestion is the primary
route of exposure studied, because exposure to As from allotment land
use occurs mainly through oral intake (CL:AIRE, 2014). In addition, a
pilot study we carried out identiﬁed air As concentrations at the al-
lotments were not signiﬁcantly elevated enough above background air
concentrations to warrant inclusion in our model. The model proposed
by Liao et al. (2008) for children was not evaluated using experimental
data, whereas the predictive performance of the other models were
tested using data from human studies included in the same publica-
tions. We adopted the model published by El-Masri and Kenyon (2008)
because it is the most recent model (hence the most informed parameter
wise) out of those considered. The El-Masri & Kenyon model comprises
9 compartments: gastrointestinal (GI) tract, liver, kidney, blood, mus-
cles, brain, skin, heart and lung. The lung compartment was included in
the model because it receives total blood ﬂow, thus mathematically
accounting for As reduction that may occur in other body tissues (El-
Masri and Kenyon, 2008). We made the following modiﬁcations to the
model: (i) we considered oxidation and reduction in the lung, liver and
kidney only, and assumed that oxidation and reduction occurs in all
perfused tissues as previously reported by Mann et al. (1996) and Yu
(1999); (ii) we ignored the oxidation and reduction reactions between
MMA(III) and MMA(V), DMA(III) and DMA(V) and treated MMA and
DMA as single species because in our laboratory analysis we tested for
total inorganic As (sum of inorganic As species); and (iii) included
biliary excretion of As from the liver as reported by Yu (1999) and Liao
et al. (2008). Fig. 1 shows the schematic representation of our resulting
modiﬁed PBPK model for As.
2.3. Cadmium
There are a number of PBTK models for Cd published in the lit-
erature (Nordberg and Kjellstrom, 1979; Choudhury et al., 2001; Amzal
et al., 2009; Ju et al., 2012; Fransson et al., 2014) based on the original
PBTK model for Cd published by Kjellstrom and Nordberg (1978) (KN
model). The KN model consists of eight compartments, describing Cd
uptake from the GI tract and the lungs, distribution of absorbed Cd to
three blood compartments, liver, kidney and ‘other tissues’, and Cd
elimination through urine and faeces. The KN model was tested using
data from studies involving Cd exposure through inhalation (Nordberg
and Kjellstrom, 1979). The model has been used in other studies (Ruiz
et al., 2010; Ju et al., 2012; Fransson et al., 2014) to simulate Cd ex-
posure through oral ingestion. It was modiﬁed by Ruiz et al. (2010) and
used to accurately predict urinary Cd concentrations following oral
ingestion using data from the National Health and Nutrition Examina-
tion Survey (NHANES). A study by Choudhury et al. (2001) also used a
modiﬁed version of the KN model to predict urinary Cd concentrations
consistent with the NHANES data.
We adopted the KN model in this study because it is the most used
model and it is also the basis for other published Cd PBTK models.
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Given that our study involves exposure through oral ingestion of food,
we excluded the inhalation pathway from the model. In addition, the
direct transfer of unabsorbed Cd to faeces was added to the modiﬁed
model to account for unabsorbed Cd. The schematic representation of
the modiﬁed PBTK model for Cd is given in Fig. 2.
2.4. Chromium
Two key models for Cr were identiﬁed in the literature. A physio-
logically-based model for the ingestion of Cr(III) and Cr(VI) by humans
was developed by O’Flaherty et al. (2001). The compartments included
in the model are the GI tract, blood (plasma and red blood cells), liver,
kidney, bone (trabecular and cortical), well- and poorly-perfused tissues
with pulmonary absorption of inhaled Cr and excretion pathways via
faeces and urine. The model was calibrated using blood and urine Cr
concentration data from controlled studies in which human volunteers
drank solutions containing Cr(III) and Cr(VI) (O’Flaherty et al., 2001).
Another PBPK model for humans orally exposed to Cr was developed by
Kirman et al. (2013). This model includes compartments for the GI tract
(stomach and intestines), blood (systemic and portal plasma and red
blood cells), liver, kidney, bone and ‘other tissues’. Model performance
was evaluated using toxicokinetic data for Cr in human tissues and
excreta obtained from the literature (Kirman et al., 2013). The model
was observed to provide a good description of Cr toxicokinetics in
humans. One key diﬀerence between these two models is that Kirman
et al. (2013) included detailed Cr toxicokinetics in the GI tract com-
partments, while O’Flaherty et al. (2001) modelled the GI tract as a
single compartment. We adopted the model by Kirman et al. (2013)
since it is the most recent model, and modiﬁed it by ignoring the de-
tailed competing toxicokinetic processes of Cr in the stomach and in-
testines, because there are published absorption rates for Cr in the GI
tract (Kirman et al., 2013; Sasso and Schlosser, 2015). Therefore, the
‘stomach’, ‘small intestines’ and ‘large intestines’ were lumped into a
single compartment (GI tract). Fig. 3 shows the structure of our mod-
iﬁed PBPK model for Cr.
2.5. Nickel
There are limited PBPK models for Ni compounds in the literature
relevant to humans. Models describing the deposition, retention and
Fig. 1. A modiﬁed version of the PBPK model for As pub-
lished by El-Masri & Kenyon (2008).
(A) Oral absorption of As(III), As(V), MMA, DMA was ac-
counted for in the GI tract. eF is faecal excretion rate of As
species (day−1), eB is biliary excretion rate of As species
(day−1), eU is urinary excretion rate of As species (day−1).
K12 to K92 refer to the calculated transfer rates (day−1) of As
species between compartments. (B) Shows the oxidation/re-
duction of inorganic arsenic in all tissues and methylation of
As(III) to MMA and DMA in kidney and liver (Liao et al.,
2008). Kox and Kred are metabolic constants (day−1) for oxi-
dation and reduction, respectively, Vmax (μmol day−1) and
Km (μmol L−1) are metabolic constants for methylation of As
(III), and i refers to the respective compartment (liver,
kidney).
Fig. 2. A modiﬁed version of the PBTK model of Cd metabolism published by Kjellström
& Nordberg (1978). Blood1 to Blood3 refer to ‘plasma other’, ‘red blood cells’ and ‘plasma
metallothionein’, respectively; C5 to C19 and CX refer to the parameters describing the
transfer of Cd between compartments as originally deﬁned by Kjellström & Nordberg
(1978).
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clearance of inhaled Ni (in the lung) have been developed (e.g., Hsieh
et al., 1999; Yu et al., 2001). However, given that inhalation route is not
the dominant pathway for allotment land use, these models were not
reviewed. The only PBTK model in the literature for human exposure to
Ni through the oral pathway is that of Sunderman et al. (1989), fol-
lowing controlled oral exposure to Ni ions. They developed the model
based on two experiments in which Ni levels in serum, urinary and
faecal excretions were monitored after 8 human subjects were given an
oral dose of Ni (as NiSO4) in either water (experiment 1) or food (ex-
periment 2). The model comprises four compartments (gut, serum,
urine and tissues) with the parameters based on model-data ﬁtting to
the two experiments. This allowed rate constants for alimentary Ni
absorption from the gut, Ni transfer rate constants from serum to tissues
and urine, and from tissues to serum to be determined. Given that our
study involves exposure through oral ingestion of food, the model
parameters provided by Sunderman et al. (1989) from experiment 2
were considered more relevant to our study than parameters from ex-
periment 1. However, Sunderman et al. (1989) did not determine the
rate transfer from tissues to serum in experiment 2, which they in-
dicated was due to the small mass of Ni absorbed from the gut into
subsequent compartments. Therefore, we used the Ni rate transfer from
tissues to serum from experiment 1 in our simulations. The unabsorbed
fraction of Ni was accounted for by adding a ‘faeces’ compartment to
the model. A schematic representation of the modiﬁed PBTK model for
Ni is given in Fig. 4.
2.6. Lead
There are a number of Pb kinetic models for humans in the litera-
ture. The most cited in the literature reviewed are the Leggett model
(Leggett, 1993), the Integrated Exposure Uptake Biokinetic (IEUBK)
model (White et al., 1998) and the O’Flaherty model (Flaherty, 1991,
1993; ; Fleming et al., 1999). The IEUBK model deals with Pb kinetics in
children only whilst our study involved adults. The Leggett model does
not account for physiological factors in detail because it utilises
‘transfer rates’ that are age-speciﬁc and regards those older than 25
years old as one age-class, which does not account for physiological
variabilities that can be associated with varying body weights (Bailey
et al., 2004; Prakash et al., 2013). Therefore, both the IEUBK and the
Leggett models were not considered suitable for this study. The
O’Flaherty model was chosen for our work because it is physiologically-
based and is only applicable to adults. Full details of the construction of
this model are provided elsewhere (O’Flaherty, 1991; O’Flaherty, 1993;
Fleming et al., 1999). Brieﬂy, the model includes 9 body compartments,
namely: the GI tract, blood, liver, kidney, bone (cortical and trabe-
cular), other tissues (well- and poorly-perfused) and the lungs. This
model has been evaluated against data from human subjects exposed to
Pb through oral and inhalation pathways (O’Flaherty, 1993). We ex-
cluded the inhalation component of this model because from our pre-
liminary investigation, air Pb concentrations at allotments were not
elevated enough above background air concentrations. In addition, we
simpliﬁed the model by neglecting the detailed Pb kinetics in the bone
associated with bone growth, since human skeletal growth is considered
to be complete by the age of 25 (O’Flaherty, 1993) and all of our study
participants were aged 30 years and above. Fig. 5 provides a schematic
representation of the modiﬁed PBPK model for Pb.
2.7. Model solutions and analysis
Each model was solved using the SimBiology application in
MATLAB (version R2016a, MathWorks®) with the mathematical equa-
tions and parameters detailed in the Supplementary Material. Given the
variation in parameter values, the stiﬀ solver ode15s was chosen to
provide accurate numerical simulations with the relative tolerance set
at the default value (0.001).
2.8. Evaluation of model performance
We sought to evaluate the predictive performance of the modiﬁed
models by comparing model simulations with data presented in the
literature. Firstly, the relationship (goodness of ﬁt) between results
from each mathematical model and the corresponding time course of
literature data were examined using linear regression (Pearson’s cor-
relation test) using a statistical level of signiﬁcance of p < 0.05.
Secondly, the predictive accuracy of the models was also assessed
using the root mean square error (RMSE) as calculated by Ju et al.
(2012) and Walther and Moore (2005)
∑= −
=
RMSE
n
C C1 ( ) .
i
n
lit s
1
2
(1)
Here, Cs and Clit refer to the simulated data and literature data values,
respectively at time point i for a total of n number of data points. We
expressed maximum Cs as a percentage of Clit to determine the mag-
nitude of over- or under-prediction of the models. RMSE explicitly
Fig. 3. A modiﬁed version of the PBPK model for Cr published by Kirman et al. (2013).
RBC refers to red blood cells. All compartments contain Cr(III) and Cr(VI). Reduction of
Cr(VI) to Cr(III) occurs in the GI tract, blood, liver, kidney, and other tissues. Cr is ex-
creted in urine mainly as Cr(III) due to rapid reduction of Cr(VI) to Cr(III) in the body
(O’Flaherty et al., 2001).
Fig. 4. A modiﬁed version of the Ni PBTK model published by Sunderman et al. (1989).
K1, Kf, K12 and K21 refer to the transfer rates of Ni between compartments and eU is the
rate constant for urinary elimination. The absorbed fraction of Ni dose in the gut (Agut)
was 0.011, as determined by Sunderman et al. (1989). The rate constant for faecal ex-
cretion of unabsorbed Ni in dose was expressed as ρK1, and ρ was calculated as (1-Agut)/
Agut.
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shows how much the model predictions deviate from the corresponding
literature data; hence RMSE gives an absolute measure of ﬁt. Statistical
analyses and processing of data were carried out using R statistical
software version 3.3.0 (R Core Team, 2016) and Microsoft Oﬃce Excel
2010.
2.9. Sensitivity analysis
Parametric sensitivity analysis was performed using sensitivity
coeﬃcients (SC) to determine which parameters were more sensitive to
change. Values of SC were calculated using the following expression
(Choudhury et al., 2001; Evans and Andersen, 2000).
⎜ ⎟= ⎛
⎝
⎞
⎠
×SC δm
δp
p
m
.
(2)
Here, δm is the change in model output (m) resulting from the change
(δp) in an input parameter value (p). An SC of zero implies that there is
no change in model output regardless of the parameter value used.
Positive and negative SC values indicate an increase in model output
with a given increase in parameter value, and a decrease in model
output with a given increase in parameter value, respectively. High SC
values indicate a model is highly sensitivity to a given parameter value
(Choudhury et al., 2001). Sensitivity analysis was performed in MA-
TLAB (using full normalisation option); input values were varied
by±50%.
3. Results and discussion
3.1. Evaluation of model performance
3.1.1. Arsenic
The modiﬁed As model was used to simulate cumulative urinary As
metabolites based on single and multiple oral doses of As in the form of
As(V) and As(III), as reported in the literature (Mann et al., 1996; El-
Masri and Kenyon, 2008; Buchet et al., 1981). Selected results from the
simulations are plotted in Fig. 6. It has been reported that inorganic As
undergoes oxidation and reduction in body tissues and methylation to
MMA and DMA in the liver and kidney (Liao et al., 2008; El-Masri and
Kenyon, 2008). Generally, studies have found DMA to be the major
metabolite in urine following exposure to inorganic As (Yu, 1999;
Buchet et al., 1981; Hughes, 2006; Hwang et al., 2002), as bio-
transformation of inorganic As to MMA and DMA occurs rapidly making
DMA the dominant metabolic species after approximately 2 days. Our
model simulations (Fig. 6) agree with this observation, with the mod-
iﬁed As model able to reproduce the literature data well (r > 0.9 for
total As in urine). The RMSE values for total inorganic As were
4.7×10−6 and 0.4 for Fig. 6(A) and (B), respectively. Further
evaluation of the model was carried out using ingestion of 6.67 μmol
(500 μg) As (Buchet et al., 1981) and 1.33 μmol (100 μg) As (El-Masri
and Kenyon, 2008). Model predictions of cumulative urinary As (total)
were within 8% of the published data in the literature. Analytical ex-
perimental procedures for determining As species in urine are often
complex and costly. Therefore, the PBPK model can be used to estimate
internal dose and urinary concentration of speciated As, thus providing
a proxy for the analysis of speciated As in urine.
The SC for all model input parameters were generated to determine
the inﬂuence of parameter variation to the model output (urinary As).
The modiﬁed As model is most sensitive to urinary excretion of As (eU)
with an SC value> 0.9. The model also showed moderate sensitivity to
As methylation constants in the kidney (Vmax and Km) and the oral
absorption constant (Ka), with SC values varying between 0.5 and 0.7.
Therefore, parameters eU, Vmax, Km and Ka for the modiﬁed As model
require more attention during simulations and model ﬁtting with
measured data. Our ﬁndings compare well with published literature.
For example, the sensitivity analysis performed by Yu (1999) for their
PBPK model for inorganic As determined that kidney Vmax coeﬃcients
and urinary elimination constants were key input parameters that af-
fected the model output.
3.1.2. Cadmium
We compared data published by Ju et al. (2012) regarding Cd in-
gestion with the concentrations of Cd in blood and urine predictd by
our modiﬁed model. Simulations were performed with all parameters
ﬁxed to the values given in the original KN model and only the
bioaccessibility values were varied to correspond to values used by Ju
et al. (2012). The creatinine values reported by Ju et al. (2012) were
used in the conversion of the predicted urinary Cd concentrations. The
predicted results and literature data are presented in Fig. 7, which
shows that predicted concentrations are in good agreement with lit-
erature data, with low RMSE values between 0.01 and 0.02 μg g−1
creatinine (r > 0.9).
We also used the dietary intake of Cd reported by Berglund et al.
(1994) in their study investigating intestinal absorption of dietary Cd in
women subjects (20–50 years of age) to predict Cd concentrations in
urine and blood following daily dietary exposure. Our simulations mi-
micked ﬁve long-term exposure scenarios lasting between 10 and 50
years which are compared in Table 1, against the results Cd measured
in urine and blood by Berglund et al. (1994). Although no corre-
sponding data (with respect to duration after exposure) was given by
the authors (this would allow direct comparison with our simulated
results) the model predictions ﬁt within the reported data ranges.
Sensitivity analysis conducted for the modiﬁed Cd model input
parameters indicated that rates for oral absorption (C5), systemic ab-
sorption (C6 and 1-C7) and urinary excretion (C7) of Cd were the input
Fig. 5. A modiﬁed version of the O’Flaherty PBPK model for Pb.
WP is well-perfused tissues, PP is poorly-perfused tissues, IRgi is the oral
intake rate of Pb (mg day−1), Agi is the Pb absorption coeﬃcient from the
GI tract (unitless), the unabsorbed fraction is represented by (1-Agi), eB is
the biliary excretion rate of Pb (day−1), eU is the urinary excretion rate of
Pb (day−1), K12 to K62 refer to the calculated Pb transfer rates (day−1)
between compartments.
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parameters that most aﬀected the model output. These four input
parameters had SC values> 0.9. The remaining parameters for the Cd
model had SC values< 0.1.
3.1.3. Chromium
The predictive performance of the Cr modiﬁed model was tested
using data published by Paustenbach et al. (1996), Kirman et al. (2013)
and Kerger et al. (1996). The results are plotted in Fig. 8.
In Fig. 8(A), the model predicts a faster urinary excretion of Cr than
the measured data in the literature. However, the cumulative urinary Cr
is consistent with literature data. The predicted results show a rea-
sonable ﬁt to the literature data following oral ingestion of Cr(III) and
Cr(VI) in single and multiple doses.
It has been observed that human absorption of Cr(VI) in the GI tract
can vary between individuals and also in the same individual at dif-
ferent times, with suggestions that physiological ﬂuids in the GI tract
Fig. 6. Comparison of predicted urinary As metabolites with experimental data in the literature.
(A) following single oral ingestion of arsenic acid (1.3× 10−4 μmol As) (Mann et al., 1996), (B) following repeated daily oral ingestion of 1.67 μmol As for 5 days (Buchet et al., 1981).
(iAs is the sum of As(III) and As(V); m, model; d, experimental data).
Fig. 7. Comparison of the predicted Cd levels in urine and blood with data reported by Ju et al. (2012). M and F refer to male and female non-smoking human subjects, respectively. Six
scenarios of Cd bioaccessibility as used by Ju et al. (2012) were simulated, I–V represent Cd bioaccessibility values (dimensionless) of 0.021, 0.032, 0.044, 0.057 and 0.094, respectively.
VI represents the scenario of using the original fraction of Cd absorbed to gastrointestinal tract and systematic circulation (0.048) adopted by Kjellström and Nordberg (1978).
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such as gastric juice and diet constituents (for instance orange juice)
can lead to poor intestinal absorption of Cr(VI), because of their ca-
pacities to reduce Cr(VI) to Cr(III) (De Flora et al., 1997; Kerger et al.,
1996; Sasso and Schlosser, 2015). Intra-individual variability in Cr(VI)
absorption due to diﬀerences in this reduction capacity has been noted
in studies involving human subjects (Finley et al., 1997; Paustenbach
et al., 1996; O’Flaherty et al., 2001). Absorption values of 0.25 day−1
for Cr(III) and 2.5 day−1 for Cr(VI) were speciﬁed by O’Flaherty et al.
(2001). In addition, we used the mean rate constants for absorption of
Cr(III) (4.6× 10−6 L h-cm−1) and Cr(VI) (3.2× 10−4 L h-cm−1) in the
small intestines given by Kirman et al. (2013) to estimate corresponding
intestinal absorption rates of 0.05 day−1 for Cr(III) and 3.5 day−1 for Cr
(VI). This suggests that oral absorption values for Cr should be carefully
Table 1
Modiﬁed model predicted urine and blood Cd concentrations and data reported by
Berglund et al. (1994).
Mixed diet High ﬁbre
Urine Blood Urine Blood
Measured concentrationsa
Median 0.10 0.23 0.09 0.25
Range 0.02–0.32 ≤0.09–0.68 ≤0.02–0.41 ≤0.09–0.96
Predicted Cd concentrations after simulating 10–50 years of daily dietary exposure to
Cd
10 years 0.04 0.29 0.05 0.38
20 years 0.08 0.33 0.08 0.43
30 years 0.10 0.38 0.11 0.48
40 years 0.12 0.39 0.13 0.51
50 years 0.13 0.41 0.14 0.53
All concentrations are expressed in μg L−1. The median daily dietary intakes of Cd re-
ported by Berglund et al. (1994) (10 μg day−1 for mixed diet and 13 μg day−1 for high
ﬁbre diet) were used in the simulations. Predicted Cd mass in urine were converted into
concentrations using the daily urine volumes reported by Berglund et al. (1994). Like-
wise, Cd loads in blood were converted to concentrations using blood volume of 5.2 L (Ju
et al., 2012).
a Berglund et al. (1994).
Fig. 8. Comparing model predicted cumulative urinary excretion of Cr and the measured urinary Cr (mean values) in human subjects. (A) for humans exposed to a single dose of 5 mg of
Cr(III) as reported by Kerger et al. (1996), (B) for humans exposed to 0.4mg of Cr(III) per day for 3 days (Kirman et al., 2013), (C) for humans exposed to a single dose of 5mg of Cr(VI) as
reported by Kerger et al. (1996), and (D) for a human volunteer exposed to 4mg Cr(VI) per day for 17 days (Paustenbach et al., 1996).
Fig. 9. Comparison of predicted urinary Ni excretion with literature data.
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selected when ﬁtting a model using experimental data. In our simula-
tions we used a range of GI tract absorption rates, 0.05–0.25 day−1 for
Cr(III) and 1–2.5 day−1 for Cr(VI) to ﬁt model predictions with the
literature data (r > 0.8, RMSE ≤0.01mg). Sensitivity analysis identi-
ﬁed the oral absorption rate as the most sensitive parameter (SC > 0.9)
in the modiﬁed Cr model. The second most sensitive parameter in the
Cr modiﬁed model was the urinary elimination rate of Cr, which had an
SC value of 0.4. Our ﬁndings are consistent with those published by
Kirman et al. (2013) who also identiﬁed a number of sensitive para-
meters to their Cr model, including parameters associated with Cr ab-
sorption in the GI tract and urinary excretion.
3.1.4. Nickel
The predictive performance of the Ni modiﬁed model was tested
using data obtained from Sunderman et al. (1989) and Nielsen et al.
(1999). The model results are presented in Fig. 9, which indicates that
the predicted urinary excretion of Ni match closely with data from
Sunderman et al. (1989) thus showing the capability of the model to
reproduce literature data (r > 0.9 with low RMSE values ranging from
0.02 to 0.9 μg). The mass fraction of Ni dose absorbed from the gut in
the experiment by Sunderman et al. (1989) was 0.7 ± 0.4% for Ni dose
ingested in food. In a similar study involving controlled ingestion of Ni
dose in food, Nielsen et al. (1999) reported a median value of Ni oral
absorption of 2.95 ± 1.32%, which is notably higher than oral ab-
sorption values reported by Sunderman et al. (1989). This may explain
why measurements of urinary Ni published by Nielsen et al. (1999)
were higher than those from the Sunderman et al. (1989) study (Fig. 9).
A range of oral absorption values of Ni in the gut were also noted in the
literature. Studies by Horak and Sunderman (1973), McNeely et al. (1972)
and McNeely et al. (1971) reported Ni oral absorption values between 1
and 1.6%. Overall, these oral absorption values indicate that faecal ex-
cretion is a major route for elimination of Ni from the human body.
The most sensitive parameters for the Ni modiﬁed model were re-
lated to oral absorption of Ni (Agut and K1), which had SC values> 0.9.
The model also showed some sensitive to the urinary elimination rate of
Ni which had an SC value of 0.7.
3.1.5. Lead
Evaluation of the modiﬁed Pb model was carried out using experi-
mental data of Rabinowitz et al. (1976), who studied the steady-state
kinetics of Pb in ﬁve healthy men (subjects A to E) with stable isotope
tracers. Since the transport of Pb throughout the body is governed by its
concentration in the plasma (O’Flaherty, 1993; Fleming et al., 1999;
Leggett 1993), Pb concentration in whole blood was calculated from the
model-predicted plasma Pb concentrations using the expression
(MacMillan et al., 2015).
⎜ ⎟⎜ ⎟
= − ×
+ ⎛
⎝
× × ⎛
⎝
+ ⎛
⎝ +
⎞
⎠
⎞
⎠
⎞
⎠
CB HCT CPLASMA
HCT CPLASMA G BIND
KBIND CPLASMA
((1 ) )
.
(3)
Here CB is Pb concentration in whole blood, HCT is the haematocrit
fraction of whole blood (0.45), CPLASMA is Pb concentration in blood
plasma, G is the ratio of unbound erythrocyte Pb concentration to
plasma Pb concentration (1.2), BIND is the Pb binding capacity of er-
ythrocytes (0.437mg Pb L−1 cell), and KBIND is the binding constant of
erythrocytes (3.72× 10−4 mg Pb L−1 cell). This allowed for compar-
ison to be made between model-predicted plasma concentrations and
Pb measurements in whole blood. Simulated results for the ﬁve subjects
are presented in Fig. 10, which shows maximum Pb concentrations si-
milar to the observations made by Rabinowitz et al. (1976).
The predicted Pb concentrations in blood were highly correlated to
the literature data (r > 0.9 for subjects A, B, D, E, and r= 0.7 for
subject C). Notably, there were fewer data points for subject C, which
could be the reason for the reduced correlation. In addition, the lit-
erature data for subject C shows a constant blood concentration beyond
day 2, while the model simulated declining concentrations (Fig. 10).
Individual variabilities (such as diﬀerences in absorption rates and
stomach clearance rates) cannot be ruled out as potential contributing
factors to this variation. Despite the reduced correlation for subject C,
the predicted maximum Pb in blood (which is relevant in understanding
exposure) was consisted with experimental data. Predicted maximum
Pb concentrations were within 10% of the literature data, apart from
subject E which recorded 38% above the literature data. Similar ob-
servations were made by O’Flaherty (1993) and Morisawa et al. (2001)
who tested their Pb models using the same data by Rabinowitz et al.
(1976); although data for subject C was not used in either of these
publications. Parametric sensitivity analysis indicated that our modiﬁed
model for Pb was most sensitive to the oral absorption coeﬃcient (Agi)
with an SC value> 0.9. The model also indicated some sensitivity to Pb
transfer rate from liver to blood (K12) with an SC value of 0.6, and to
Pb transfer from blood to liver (K21) with an SC value of 0.4.
3.2. Application of the models in planning our biomonitoring study
The modiﬁed models for As, Cd, Cr, Ni and Pb were used to predict
optimal times for the collection of biological samples during our bio-
monitoring study. The aim was to identify the best time points, fol-
lowing oral ingestion of allotment produce, at which to collect urine
and blood samples (the biomarkers of exposure) given their expected
low element concentrations. Model results would thus maximise the
potential of detecting these elements in biological samples.
The simulated element doses (mg day−1) were calculated based on
the following considerations:
a) Average produce concentrations recorded during our preliminary
investigation. For Cd, we assumed a value equivalent to the limit of
detection (0.03mg kg−1) because all samples recorded Cd con-
centrations below the limit of detection;
b) A produce consumption rate of 3.34 (g−1 fw kg−1 bw day−1) for a
‘high end’ consumer, derived from the data used in the CLEA model
(as illustrated in Table 2). This consumption rate relates to CLEA age
classes 17 and 18, which correspond to adults aged between 16 and
65 (age class 17) and 65–75 (age class 18), respectively. Our study
participants are aged over 30 years old.
c) An average adult body weight of 70 kg (Brown et al., 1997); and
d) Short durations of exposure (1, 3 and 7 days) were simulated to
mimic hypothetical minimal (worst-case) exposure scenarios.
The predicted optimal sample collections times are presented in
Table 3. Model predictions indicate that at very low levels of exposure,
detection of Cd and Cr in urine might not be achievable, unless the
participants have higher intake than simulated. We relied on a detec-
tion limit of 0.01 μg L−1 using inductively coupled plasma mass spec-
trometry (ICP-MS). Higher intake would increase the ‘window’ of op-
timal sampling times. On the contrary, detection of urinary As (total)
and Ni, and blood Pb would not prove diﬃcult. These optimal times
informed the sampling frequencies adopted in our biomonitoring study.
4. Conclusions
Overall, our ﬁve modiﬁed models for oral ingestion of As, Cd, Cr, Ni
and Pb have shown good agreement with literature data. As such, they
can be considered in the analysis of human exposure to the selected
elements when only the oral ingestion pathway requires investigation,
thus simplifying the overall model structures, in some cases to a large
degree. Model parameters can also be adjusted to reﬂect the actual
exposure characteristics being investigated.
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Our work has demonstrated that mathematical modelling can be a
useful tool in planning the collection of human studies during, in this
case, a biomonitoring study. It indicates the period during which the
likelihood of sample detection is highest, thus informing the best per-
iods to collect samples – a time consuming and costly task in itself. We
envisage the use of this technique could be more widely employed in
environmental studies and provides a relatively inexpensive means for
optimising sample collection in conjunction with the known biology
and chemistry of the respective compounds.
Fig. 10. Comparison of our modiﬁed PBPK model predicted Pb concentration in blood with measured Pb in whole blood from the Rabinowitz et al. (1976) study. Duration of study refers
to time after the beginning of controlled ingestion of Pb isotope. Ingestion periods for Subjects A (204 μg day−1), B (185 μg day−1) and D (105 μg day−1) were 104, 124 and 82 days,
respectively. Subject C ingested 68 μg day−1 for 1 day, while subject E ingested 99 μg day−1 for the ﬁrst 8 days and again from days 42–52.
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Calculation of allotment-related produce consumption rates from CLEA data.
CLEA Produce
Categoryc
Produce Consumption for CLEA Age Class 17–18 (Adults)a,b
Consumption
Rated
Homegrown
fraction
Allotment related
Consumption Rated,e
(average) (high
end)
(average) (high
end)
Green 2.94 0.05 0.33 0.15 0.97
Root 1.40 0.06 0.40 0.08 0.56
Tuber 1.79 0.02 0.13 0.04 0.23
Herbaceous 1.61 0.06 0.40 0.10 0.64
Shrub 0.22 0.09 0.60 0.02 0.13
Tree 2.97 0.04 0.27 0.12 0.80
Total 0.50 3.34
a Environment Agency (2009).
b We assumed individuals consuming all CLEA produce categories.
c Vegetables (Green, Root, Tuber) and Fruits (Herbaceous, Shrub, Tree).
d Units (g fw kg−1 bw day−1), fw (fresh weight, produce), bw (body weight).
e Allotment-related consumption rate is the product of ‘consumption rate’ and
‘homegrown fraction’.
Table 3
Planning of biomonitoring using model predictions.
Element Oral dose
(mg day−1)
Exposure
Duration
(days)
Optimal
sampling time
following
exposure
(range)
Corresponding
concentration (ppb) in
urinea (As, Cd, Cr, Ni)
and bloodb (Pb) at
optimal time
As 0.44
(5.9 μmol)
1 7–14 days 2.6–9.0
3 7–21 days 9–24
7 10–30 days 18–43
Cd 0.004 1 N/A <0.01
3 N/A <0.01
7 N/A <0.01
Cr 0.1 1 N/A <0.01
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3 10–20 days 1.4–3.8
7 14–30 days 1.4–4.8
Pb 0.47 1 15–90 days ≥0.3
3 15–90 days ≥1.0
7 15–90 days ≥2.3
N/A implies ‘not applicable’ (very low concentrations predicted).
a Urinary concentrations were calculated using urine volume of 1.4 L day−1 (Ju et al.,
2012).
b Blood concentrations were calculated using blood volume of 5.2 L day−1 (Ju et al.,
2012).
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